TREATING MYELOMA CAN SEEM LIKE A MARATHON
WOULD YOU TAKE OFF YOUR SHOE WHEN RUNNING A MARATHON?
Continuous treatment with a proteasome inhibitor (PI)–based regimen is associated with clinical benefits.1 However, most patients who have had 1 prior therapy only receive PIs for 4 to 7 months.2-4
The NINLARO® (ixazomib) regimen extended PFS by ~6 months (median: 20.6 vs 14.7 months) vs placebo regimen in patients with multiple myeloma who have received at least 1 prior therapy.1*†
NINLARO is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.SEE THE PATH TO EXTENDED PFS